Progressive pulmonary fibrosis: all roads lead to Rome (but not all at the same speed)
- PMID: 36202405
- DOI: 10.1183/13993003.01449-2022
Progressive pulmonary fibrosis: all roads lead to Rome (but not all at the same speed)
Conflict of interest statement
Conflict of interest: V. Cottin reports grants from Boehringer Ingelheim; consulting fees from Boehringer Ingelheim, Roche, Shionogi, RedX, Pure Tech, Celgene/BMS, AstraZeneca, CSL Behring, Sanofi, United Therapeutics and Pliant; lecture fees and travel support from Boehringer Ingelheim and Roche; data and safety monitoring board participation with Galapagos and Galecto; adjudication committee role with Fibrogen; outside the submitted work. C. Valenzuela reports consulting fees, fees for lectures and support for attending meetings from Boehringer Ingelheim and Roche; outside the submitted work.
Comment on
-
Prevalence and characteristics of progressive fibrosing interstitial lung disease in a prospective registry.Eur Respir J. 2022 Oct 6;60(4):2102571. doi: 10.1183/13993003.02571-2021. Print 2022 Oct. Eur Respir J. 2022. PMID: 35273032
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical